GVG Research News

Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 for the Treatment of Cocaine and Methamphetamine Addiction

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that the Company will continue to develop CPP-109 (Catalyst’s version of vigabatrin) for the treatment of cocaine and methamphetamine addiction.  9/30/2009

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

Catalyst Pharmaceutical Partners, Inc. has announced that data from the trial showed that CPP-109 did not demonstrate statistical significance in the primary endpoint -- that a significantly larger proportion of CPP-109-treated subjects than placebo-treated subjects were cocaine-free during the last two weeks of the treatment period (Weeks 11 and 12).  5/29/2009

Hope for Treating Relapse to Methamphetamine Abuse

A new study at Brookhaven Lab suggests that vigabatrin (a.k.a. gamma vinyl-GABA, or GVG) blocks drug-seeking behavior in animals previously trained to associate methamphetamine with a particular environment. Specifically, animals pre-treated with vigabatrin lost interest in spending time in a location where they had previously been given methamphetamine.  11/13/2008

Addiction Treatment Proves Successful in Animal Weight Loss Study

Vigabatrin, a medication proposed as a potential treatment for drug addiction by scientists at the U.S. Department of Energy’s Brookhaven National Laboratory, also leads to rapid weight loss and reduced food intake according to a new animal study from the same research group.  8/20/2008

Catalyst Pharmaceutical Partners Begins Enrollment for its U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has initiated enrollment of patients for its 180-patient, U.S. Phase II clinical trial evaluating the use of CPP-109 in treating patients with cocaine addiction. CPP-109, an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release, is Catalyst's lead compound, vigabatrin.  1/25/2008

Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced positive initial top-line results from an investigator-initiated Phase II double-blind, placebo-controlled trial, which demonstrates that vigabatrin is effective for the treatment of cocaine addiction. Catalyst's lead compound, CPP-109, is bioequivalent to vigabatrin.  12/7/2007

Catalyst Pharmaceutical Partners, Inc. Initiates U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Dependence

Catalyst Pharmaceutical Partners, Inc., a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial of CPP-109 in patients with cocaine dependence. CPP-109, an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release, is Catalyst's lead compound, vig  7/10/2007

Catalyst Pharmaceutical Partners Says FDA Has Accepted IND Application for CPP-109 to Treat Cocaine Addiction

Catalyst Pharmaceutical Partners has announced that the U.S. Food and Drug Administration has allowed its Investigational New Drug Application to evaluate Catalyst's lead compound, CPP-109, as a potential pharmaceutical therapy for treating cocaine addiction. Catalyst received an exclusive worldwide license from Brookhaven Science Associates, operator of Brookhaven National Laboratory, for the use of the drug gamma vigabatrin or GVG for its application in treating drug addiction.  1/3/2005

Proposed Addiction Treatment Successful, Safe in Second Small Trial

A second, small-scale clinical trial of a proposed addiction treatment originally investigated at Brookhaven National Laboratory has produced favorable results in the treatment of long-term addiction to methamphetamine and/or cocaine, with no visual side effects in any of the 30 patients enrolled.  11/15/2004

New Study Shows Hope for Treating Inhalant Abuse

A new study by scientists at Brookhaven National Laboratory suggests that vigabatrin may block the addictive effects of toluene, a substance found in household products commonly used as inhalants. These results broaden the promise of GVG as a potential treatment for a variety of addictions.  9/30/2004

Results From First Clinical Trial Using GVG to Treat Addiction

This is the first human clinical data showing that gamma vinyl-GABA (GVG, vigabatrin) holds promise as a pharmacological treatment for cocaine addiction.  9/22/2003

Proposed Addiction Treatment Blocks Environment-Triggered Craving

Anecdotal reports suggest that addicts crave drugs when they visit places where they've routinely used drugs. Now, a new study funded by the U.S. Department of Energy and conducted at Brookhaven Lab shows that, in animals, such environmental cues trigger measurable increases in dopamine, a brain chemical closely linked with addiction.  3/7/2001

Brookhaven Lab Awards License to David Pharmaceuticals, Inc. for Potential Addiction Treatment

The U.S. Department of Energy's Brookhaven National Laboratory has licensed to David Pharmaceuticals, Inc., of Burlingame, California, the use of the drug vigabatrin for its potential application in treating addiction.  9/9/1999

Epilepsy Drug Stops Nicotine's Effects in Animals

Smokers who want to kick the habit may find powerful help from a European epilepsy drug that already has shown promise in treating cocaine's effects in animals, U.S. Secretary of Energy Bill Richardson announced today.  12/2/1998

Epilepsy Drug Found to Stop Cocaine's Effects in Animals

An inexpensive epilepsy drug may prove to be a highly effective pharmaceutical treatment for cocaine addiction. In addition, preliminary data suggests that it may be useful for the treatment of other addictions.  8/5/1998

Last Modified: May 20, 2009
Please forward all questions about this site to: Denise Monteleone

One of ten national laboratories overseen and primarily funded by the Office of Science of the U.S. Department of Energy (DOE), Brookhaven National Laboratory conducts research in the physical, biomedical, and environmental sciences, as well as in energy technologies and national security. Brookhaven Lab also builds and operates major scientific facilities available to university, industry and government researchers. Brookhaven is operated and managed for DOE's Office of Science by Brookhaven Science Associates, a limited-liability company founded by Stony Brook University, the largest academic user of Laboratory facilities, and Battelle, a nonprofit, applied science and technology organization.

Privacy and Security Notice  | Contact Web Services for help